Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)
Clinical trial NCT03486873 · RECRUITING
Trial details
- NCT number
- NCT03486873
- Sponsor
- Merck Sharp & Dohme LLC
- Status
- RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2018-08-21
- Primary completion
- 2043-08-04
- Enrollment
- 3500
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.